These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7277182)

  • 1. Binding of several loop diuretics to serum albumin and human serum from patients with renal failure and liver disease.
    Goto S; Yoshitomi H; Miyamoto A; Inoue K; Nakano M
    J Pharmacobiodyn; 1980 Dec; 3(12):667-76. PubMed ID: 7277182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further investigations on the binding of loop diuretics to serum proteins from patients with liver disease.
    Goto S; Yoshitomi H; Miyamoto A; Yamada H; Fujii S; Nakayama T; Fujiwara K
    J Pharmacobiodyn; 1981 Nov; 4(11):865-73. PubMed ID: 7328487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal actions of piretanide and three other "loop" diuretics.
    McNabb WR; Noormohamed FH; Brooks BA; Lant AF
    Clin Pharmacol Ther; 1984 Mar; 35(3):328-37. PubMed ID: 6697640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loop-acting diuretics do not bind to Tamm-Horsfall urinary glycoprotein.
    Brunisholz MC; Lynn KL; Hunt JS
    Clin Sci (Lond); 1987 Sep; 73(3):305-10. PubMed ID: 3652635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency.
    Berg KJ; Walstad RA; Bergh K
    Br J Clin Pharmacol; 1983 Mar; 15(3):347-53. PubMed ID: 6342640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein binding and bilirubin displacing properties of bumetanide and furosemide.
    Turmen T; Thom P; Louridas AT; LeMorvan P; Aranda JV
    J Clin Pharmacol; 1982; 22(11-12):551-6. PubMed ID: 7161408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
    Takamura N; Maruyama T; Otagiri M
    Clin Chem; 1997 Dec; 43(12):2274-80. PubMed ID: 9439444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence].
    Lebedev AA; Samokrutova OV
    Farmakol Toksikol; 1989; 52(3):40-3. PubMed ID: 2792351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bumetanide binding to normal albumins and to albumin in renal failure.
    Howlett MR; Auld WH; Murdoch WR; Skellern GG
    Biopharm Drug Dispos; 1993 Aug; 14(6):503-10. PubMed ID: 8218968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piretanide: a loop-active diuretic. Pharmacology, therapeutic efficacy and adverse effects.
    Marsh JD; Smith TW
    Pharmacotherapy; 1984; 4(4):170-80. PubMed ID: 6384944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment.
    Howlett MR; Skellern GG; Auld WH; Murdoch WR
    Eur J Clin Pharmacol; 1990; 38(6):583-6. PubMed ID: 2373133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Clissold SP; Brogden RN
    Drugs; 1985 Jun; 29(6):489-530. PubMed ID: 3891305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin binding of bumetanide.
    Robertson A; Karp W
    Dev Pharmacol Ther; 1986; 9(4):241-8. PubMed ID: 3757731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog.
    Cohen MR; Hinsch E; Vergona R; Ryan J; Kolis SJ; Schwartz MA
    J Pharmacol Exp Ther; 1976 Jun; 197(3):697-702. PubMed ID: 932999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the loop diuretic piretanide in renal failure.
    Walter U; Röckel A; Lahn W; Heidland A; Heptner W
    Eur J Clin Pharmacol; 1985; 29(3):337-43. PubMed ID: 4076330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein binding characteristics of bumetanide.
    Walker PC; Berry NS; Edwards DJ
    Dev Pharmacol Ther; 1989; 12(1):13-8. PubMed ID: 2721330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency.
    Marone C; Reubi FC; Lahn W
    Eur J Clin Pharmacol; 1984; 26(4):413-8. PubMed ID: 6734705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and response to bumetanide and furosemide.
    Brater DC
    Am J Cardiol; 1986 Jan; 57(2):20A-25A. PubMed ID: 3511654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of furosemide binding to serum albumin induced by increased level of fatty acid.
    Bojko B; Sułkowska A; Maciazek-Jurczyk M; Równicka J; Pentak D; Sułkowski WW
    J Pharm Biomed Anal; 2010 Jan; 51(1):273-7. PubMed ID: 19709838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P
    Scand J Urol Nephrol Suppl; 1988; 111():1-66. PubMed ID: 3201162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.